SOPHIA ANTIPOLIS, FRANCE -- (MARKET WIRE) -- March 29, 2007 -- NicOx S.A. (Eurolist : COX) today announced that additional information has been communicated by Pfizer Inc (NYSE : PFE) regarding the design of the first clinical study for PF-03187207 in patients with glaucoma and ocular hypertension.
